Circuit of Specific Medications at Aziza Othmana Hospital: The Case of Chemotherapy
##plugins.themes.academic_pro.article.main##
Abstract
Introduction: The circuit of specific medicines at Aziza Othmana Hospital is a complex process involving various healthcare professionals. The
hospital pharmacy has implemented a dedicated system to ensure the management of these vital treatments.
Aim: The aim of this study was to examine the current circuit of specific medicines within a hospital pharmacy and to propose areas for improvement to enhance its safety.
Methods: A retrospective descriptive study was conducted within the pharmacy department of Aziza Othmana Hospital over a period extending
from January 2024 to August 2024.
Results: The analysis of the circuit identified six main stages: procurement, ordering, receiving, storage, preparation, and dispensing. Procurement,
which depends on the type of health coverage (National Health Insurance (CNAM) or indigent patients), is often a source of delays. A total of
230 patients treated with specific cytotoxic medicines and managed within the pharmacy department of Aziza Othmana Hospital in Tunis were included. The mean age of patients was 53.75 years (SD = 17.89). The sex ratio (M/F) was 1.23. The hospital pharmacy did not recover the
treatment for 8% of patients (19 patients), for whom chemotherapy cycles had been advanced.
Conclusion: The circuit of specific medicines at Aziza Othmana Hospital presents weaknesses that compromise access to treatments. Better
coordination among stakeholders is required. Placing the patient at the center of the process will improve the quality of care and strengthen trust
in the system.
Keywords:
Chemotherapy, Anticancer drugs, Supply chain, Hospital pharmacy##plugins.themes.academic_pro.article.details##
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
- Cubaynes MH, Noury D, Dahan M, Falip E. Circuit du médicament à l'hôpital [Internet]. Paris: IGAS; 2011. [Consulté le 9 novembre 2024]. Consultable à l'URL: https://www.esante-centre.fr/ portail_pro/minisite_22/media-files/48482/Rapport-IGAS_Circuit-medicament-hopital.pdf
- Rekik S. CNAM : Médicaments spécifiques, un gouffre béant [Internet]. Tunis: Réalités Magazine; 15/12/2014. [Consulté le 12 novembre 2024]. Consultable à l'URL: https://realites.com.tn/fr/cnam-medicaments-specifiques-un-gouffre-beant/
- N'dhatz Comoe E, Koffi KG, Ayemou R, Nanho Danho C, Alla D, Kouakou B, et al. Prévalence et incidence des hémopathies malignes au CHU de Yopougon. Rev Int Sci Med. Juil 2012;14(3):205-8.
- Drouet F, Cahu X, Pointreau Y, Denis F, Mahé MA. Lymphomes malins non hodgkiniens. Cancer Radiother. Nov 2010;14:S210-29.
- Harizi C, Bellali H, Hchaichi A, Hamzaoui A, Kouni Chahed M. Estimation du coût de la prise en charge du cancer broncho-pulmonaire en Tunisie. East Mediterr Health J. Oct 2018;24(10):988-93.
- Quenon JL, de Sarasqueta AM. Évaluation de la sécurité du circuit du médicament dans 19 établissements de santé aquitains Projet SECURIMED. Risques & Qualité. Déc 2006;3(4):209-15.
- Hughes D. L’accès aux médicaments anticancéreux onéreux au Canada: une comparaison entre le Québec, l'Ontario et la Colombie-Britannique. Prat Organ Soins. Jan-Mar 2012;43(1):9-18.
- Guilhot F, Rouësse J, Bouvenot G, Dreno B, Facon T, Gorin NC, et al. Médicaments anticancéreux onéreux : Disponibilité et soutenabilité économique. Bull Acad Natl Med. Nov 2024;208(1):9-24.
- Kucukarslan SN, Peters M, Mlynarek M, Nafziger DA. Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch Intern Med. 2003 Sep 22;163(17):2014.
- Kundig F. Médicaments look-alike, sound-alike : un enjeu important dans le domaine de l'infectiologie. Rev Med Suisse. 12 Oct 2011;312(36):1955-61